UGH Syndrome Resolution after IOL Explantation and Concomitant Carlevale IOL Implantation.
Glaucoma
hyphema
scleral fixated IOL
uveitic glaucoma
uveitis
Journal
Ocular immunology and inflammation
ISSN: 1744-5078
Titre abrégé: Ocul Immunol Inflamm
Pays: England
ID NLM: 9312169
Informations de publication
Date de publication:
07 Feb 2023
07 Feb 2023
Historique:
entrez:
7
2
2023
pubmed:
8
2
2023
medline:
8
2
2023
Statut:
aheadofprint
Résumé
To examine the use of Carlevale IOL placement in patients with UGH, and to evaluate surgical outcomes. In this retrospective study, 28 patients with UGH syndrome that were subjected to IOL explantation and concomitant Carlevale IOL implantation were included in the study. Information about VA, IOP, number of glaucoma medication, need for glaucoma surgery, presence of hemorrhage and inflammation were recorded up to 6 months after the procedure. We found a statistically significant increase in mean visual acuity and complete resolution of uveitis in all patients. Mean IOP and the mean number of glaucoma medications were significantly decreased postoperatively, while 14% of patients required additional glaucoma surgery. IOL explantation and concomitant Carlevale IOL implantation may provide a viable solution for UGH syndrome resolution, increases visual acuity, and decreases the need for glaucoma medication.
Identifiants
pubmed: 36749924
doi: 10.1080/09273948.2023.2169716
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM